Arvinas (NASDAQ:ARVN) Trading 4% Higher - What's Next?

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) shot up 4% on Thursday . The stock traded as high as $9.09 and last traded at $9.05. 849,142 shares changed hands during trading, a decline of 8% from the average session volume of 921,891 shares. The stock had previously closed at $8.70.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ARVN. Wells Fargo & Company set a $26.00 price objective on shares of Arvinas and gave the company an "overweight" rating in a report on Wednesday, March 12th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arvinas in a research report on Friday, February 7th. BTIG Research assumed coverage on shares of Arvinas in a research report on Tuesday, December 10th. They set a "buy" rating and a $69.00 target price on the stock. BMO Capital Markets set a $20.00 price target on shares of Arvinas and gave the stock an "outperform" rating in a report on Wednesday, March 12th. Finally, Citigroup dropped their price target on Arvinas from $28.00 to $19.00 and set a "neutral" rating on the stock in a research note on Friday, March 7th. Five analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, Arvinas presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.47.

Arvinas Price Performance

The stock has a 50 day simple moving average of $16.24 and a two-hundred day simple moving average of $21.23. The company has a market cap of $592.13 million, a price-to-earnings ratio of -3.11 and a beta of 1.95.

Remove Ads

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter last year, the firm posted ($2.53) EPS. As a group, research analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current year.

Insider Activity

In related news, CEO John G. Houston sold 31,338 shares of the company's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the sale, the chief executive officer now directly owns 1,157,480 shares in the company, valued at approximately $19,353,065.60. This represents a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Noah Berkowitz sold 8,658 shares of Arvinas stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total transaction of $74,372.22. Following the completion of the transaction, the insider now owns 110,023 shares of the company's stock, valued at $945,097.57. This represents a 7.30 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,230 shares of company stock valued at $769,402. 5.23% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Arvinas

Several institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new stake in shares of Arvinas in the fourth quarter valued at approximately $28,000. KBC Group NV grew its position in Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock worth $55,000 after purchasing an additional 1,255 shares during the last quarter. Quantbot Technologies LP raised its holdings in shares of Arvinas by 147.3% in the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock valued at $108,000 after buying an additional 2,601 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Arvinas during the fourth quarter worth about $171,000. Finally, Tema Etfs LLC purchased a new position in shares of Arvinas during the fourth quarter worth about $227,000. Hedge funds and other institutional investors own 95.19% of the company's stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.